keyword
MENU ▼
Read by QxMD icon Read
search

Vaginal atrophy

keyword
https://www.readbyqxmd.com/read/28640166/missing-documentation-in-breast-cancer-survivors-genitourinary-syndrome-of-menopause
#1
Elise D Cook, Elena I Iglehart, George Baum, Leslie L Schover, Lonzetta L Newman
OBJECTIVE: Breast cancer survivors often take hormonal treatments to prevent the recurrence of breast cancer, particularly aromatase inhibitors that can worsen the symptoms of genitourinary syndrome of menopause (GSM) such as dyspareunia, dysuria, and urinary incontinence, all of which may adversely affect survivors' quality of life. Few breast cancer survivors experiencing GSM receive adequate assessment or treatment. METHODS: In this descriptive study, we reviewed medical records for documented GSM and any treatments administered or referrals for treatment in 800 female patients who visited the Breast Cancer Survivorship Clinic at a comprehensive cancer center between July 1, 2010 and June 30, 2011, either at least 5 years after completion of treatment for invasive breast cancer or at least 6 months after completion of treatment for ductal carcinoma in situ...
June 19, 2017: Menopause: the Journal of the North American Menopause Society
https://www.readbyqxmd.com/read/28640161/combined-data-of-intravaginal-prasterone-against-vulvovaginal-atrophy-of-menopause
#2
Fernand Labrie, David F Archer, Céline Martel, Mario Vaillancourt, Marlene Montesino
OBJECTIVE: To analyze the effects of intravaginal prasterone obtained in the three randomized clinical studies performed in postmenopausal women suffering from moderate to severe (MS) dyspareunia due to vulvovaginal atrophy (VVA). METHODS: In three independent 12-week prospective, randomized, double-blind, and placebo-controlled clinical studies, the effect of daily intravaginal 0.50% (6.5 mg) prasterone was examined on four co-primary objectives in women having MS pain during sexual activity (dyspareunia), identified as their most bothersome symptom (MBS) of VVA at baseline...
June 19, 2017: Menopause: the Journal of the North American Menopause Society
https://www.readbyqxmd.com/read/28640158/vasomotor-symptoms-are-associated-with-depressive-symptoms-in-community-dwelling-older-women
#3
Berihun M Zeleke, Robin J Bell, Baki Billah, Susan R Davis
OBJECTIVE: To assess the prevalence of, and factors associated with, moderate-to-severe depressive symptoms in community-dwelling older Australian women. METHODS: A questionnaire-based, cross-sectional study was conducted amongst community-dwelling older women. Participants were recruited between April and August 2014 from a national database based on the electoral roll. Depressive symptoms were assessed by the Beck Depression Inventory-II (BDI-II) tool. Vasomotor symptoms (VMS), vulvovaginal atrophy (VVA), and pelvic floor symptoms were assessed using validated questionnaires...
June 19, 2017: Menopause: the Journal of the North American Menopause Society
https://www.readbyqxmd.com/read/28635978/vaginal-testosterone-for-management-of-aromatase-inhibitor-related-sexual-dysfunction-an-integrative-review
#4
Emily A Lemke, Lydia T Madsen, Joyce E Dains
PROBLEM IDENTIFICATION: Women taking aromatase inhibitors (AIs) as part of the management of hormone receptor-positive breast cancer experience more symptoms of sexual dysfunction, including vaginal atrophy, as opposed to postmenopausal women and women treated with tamoxifen (Nolvadex®). Vaginal testosterone could be an alternative to estrogen, which is contraindicated in this population.
. LITERATURE SEARCH: A systematic review was completed by searching PubMed and Scopus databases...
May 1, 2017: Oncology Nursing Forum
https://www.readbyqxmd.com/read/28622049/the-efficacy-and-safety-of-estriol-to-treat-vulvovaginal-atrophy-in-postmenopausal-women-a-systematic-literature-review
#5
C Rueda, A M Osorio, A C Avellaneda, C E Pinzón, O I Restrepo
OBJECTIVES: To evaluate the efficacy and safety of estriol for the treatment of vulvovaginal atrophy in postmenopausal women. METHODS: A systematic literature review was performed. We searched the following electronic databases: Medline, Cochrane, Embase, Lilacs, CINHAL and Google Scholar. The studies selected included controlled clinical trials and quasi-experimental studies. Selections were made in pairs and independently, first by title and abstract and then complete texts...
June 16, 2017: Climacteric: the Journal of the International Menopause Society
https://www.readbyqxmd.com/read/28610687/assessing-the-thickness-of-the-vaginal-wall-and-vaginal-mucosa-in-pre-menopausal-versus-post-menopausal-women-by-transabdominal-ultrasound-a-feasibility-study
#6
Adrian Balica, Daniella Wald-Spielman, Katherine Schertz, Susan Egan, Gloria Bachmann
OBJECTIVE: As life expectancy increases, the number of women reporting adverse genito-urinary symptoms (genitourinary syndrome of menopause; GSM) from menopause, including vaginal dryness and sexual pain, also will increase. Current objective measurements of vaginal atrophy such as maturation index require vaginal swabs and are invasive; at present, no minimally invasive measurements exist. The purpose of this study was to assess whether total vaginal wall thickness (TVT) and total vaginal mucosa thickness (TMT) as measured by transabdominal ultrasound could qualify as additional objective markers of vaginal wall thinning which could be related to menopausal status...
August 2017: Maturitas
https://www.readbyqxmd.com/read/28608667/dynamic-quadripolar-radiofrequency-treatment-of-vaginal-laxity-menopausal-vulvo-vaginal-atrophy-12-month-efficacy-and-safety
#7
Franco Vicariotto, Francesco DE Seta, Valentina Faoro, Mauro Raichi
BACKGROUND: Twelve-month extension of a previous spontaneous exploratory study investigating safety and efficacy of a new low-energy dynamic quadripolar radiofrequency (DQRF) device in: A) premenopausal women with symptoms of vaginal laxity, with special reference to dysuria, urinary incontinence and unsatisfactory sexual life (vaginal laxity arm of the study); B) postmenopausal women with vulvovaginal atrophy/genitourinary syndrome of menopause (VVA/GSM) and VVA/GSM-related symptoms (VVA/GSM arm of the study)...
August 2017: Minerva Ginecologica
https://www.readbyqxmd.com/read/28562130/effects-of-ospemifene-on-vaginal-epithelium-of-post-menopausal-women
#8
Stefania Alvisi, Maurizio Baldassarre, Valentina Martelli, Giulia Gava, Renato Seracchioli, Maria Cristina Meriggiola
Ospemifene is a selective estrogen receptor modulator used for the treatment of vulvo-vaginal atrophy (VVA) in post-menopausal women. No direct evidence of its effects on histological features of the human vagina has been reported. To evaluate the effects of ospemifene on histological parameters, glycogen content, proliferation, and estrogen receptor α expression (ERα) of vaginal epithelium in post-menopausal women. Thirty-two post-menopausal women undergoing surgical procedures were enrolled. Sixteen subjects taking ospemifene at the time of inclusion (OSP) were compared to 16 subjects not taking any hormone (CTL)...
May 31, 2017: Gynecological Endocrinology
https://www.readbyqxmd.com/read/28539177/relationship-between-changes-in-vulvar-vaginal-atrophy-and-changes-in-sexual-functioning
#9
JoAnn V Pinkerton, Andrew G Bushmakin, Barry S Komm, Lucy Abraham
OBJECTIVE: Conjugated estrogens/bazedoxifene (CE/BZA) has demonstrated benefit in vulvar-vaginal atrophy (VVA, part of genitourinary syndrome of menopause) and the sexual function domain of the Menopause-specific Quality of Life (MENQOL) questionnaire. The study's objective was to determine the relationship of VVA symptoms and clinical parameters with MENQOL sexual functioning in postmenopausal women receiving VVA treatment. STUDY DESIGN: Post hoc analysis data were derived from the 12-week SMART-3 trial, which evaluated CE/BZA's effect on VVA in nonhysterectomized postmenopausal women (aged 40-65 years) experiencing one or more moderate to severe VVA symptoms (dryness, itching/irritation, pain with intercourse) and vaginal pH>5...
June 2017: Maturitas
https://www.readbyqxmd.com/read/28523261/rejuvenation-using-platelet-rich-plasma-and-lipofilling-for-vaginal-atrophy-and-lichen-sclerosus
#10
Seok Hwan Kim, Eun Soo Park, Tae Hee Kim
Vaginal atrophy is a common condition among peri- and post-menopausal women. Symptoms of vaginal dryness, pruritus, irritation, loss of subcutaneous fat, sparse pubic hair and dyspareunia occur due to decreased estrogen level. Estrogen-based treatments are effective. But many patients are reluctant to be treated due to health concerns. As alternatives, we explored the efficacy of platelet-rich plasma (PRP) and lipofilling. A 67-year-old female patient with vaginal atrophy was referred to our department. Treatment using estrogen cream had failed to improve patient's symptoms...
April 2017: Journal of Menopausal Medicine
https://www.readbyqxmd.com/read/28503946/fractional-co2-laser-therapy-a-new-challenge-for-vulvovaginal-atrophy-in-postmenopausal-women
#11
G P Siliquini, V Tuninetti, V E Bounous, F Bert, N Biglia
OBJECTIVE: To evaluate the effects of CO2 laser in the treatment of vulvovaginal atrophy (VVA) in postmenopausal women. METHODS: VVA was assessed in 87 postmenopausal women (mean age 58.6 ± 6.9 years) before and after the treatment. The protocol consisted of three monthly treatments and included the treatment of vulva. Subjective measures included VAS (Visual Analog Scale) both for vaginal dryness and dyspareunia; DIVA (Day-by-day Impact of Vaginal Aging); a questionnaire on treatment satisfaction and one about the degree of pain during the procedure...
May 15, 2017: Climacteric: the Journal of the International Menopause Society
https://www.readbyqxmd.com/read/28492016/vaginal-rejuvenation-using-energy-based-devices
#12
REVIEW
Cheryl Karcher, Neil Sadick
Physiologic changes in a woman's life, such as childbirth, weight fluctuations, and hormonal changes due to aging and menopause, may alter the laxity of the vaginal canal, damage the pelvic floor, and devitalize the mucosal tone of the vaginal wall. These events often lead to the development of genitourinary conditions such as stress urinary incontinence; vaginal atrophy; dryness; and physiologic distress affecting a woman's quality of life, self-confidence, and sexuality. Various treatment modalities are currently available to manage these indications, varying from invasive vaginal surgery to more benign treatments like topical vaginal hormonal gels or hormone-replacement therapy...
September 2016: International Journal of Women's Dermatology
https://www.readbyqxmd.com/read/28490209/retrospective-analysis-in-46-women-with-vulvovaginal-atrophy-treated-with-ospemifene-for-12-weeks-improvement-in-overactive-bladder-symptoms
#13
Michele Carlo Schiavi, Marzio Angelo Zullo, Pierangelo Faiano, Ottavia D'Oria, Giovanni Prata, Vanessa Colagiovanni, Andrea Giannini, Chiara Di Tucci, Giorgia Perniola, Violante Di Donato, Marco Monti, Ludovico Muzii, Pierluigi Benedetti Panici
AIMS: The aim of this study was to assess the effectiveness and safety of ospemifene in the improvement of overactive bladder (OAB) symptoms in postmenopausal women affected by vulvovaginal atrophy (VVA). METHODS: Forty-six postmenopausal patients affected by VVA with OAB syndrome were enrolled for the study. All patients received Ospemifene 60 mg for 12 weeks. Clinical examination, 3-day voiding diary, urodynamic testing, ultrasound measurement of endometrial and bladder wall thickness (BWT) and the Vaginal Health Index (VHI) were performed at baseline and 12 weeks...
May 11, 2017: Gynecological Endocrinology
https://www.readbyqxmd.com/read/28440666/relationship-between-delivery-modes-and-genitourinary-syndrome-among-postmenopausal-women
#14
M Yaralizadeh, P Abedi, P Salehinejad
OBJECTIVES: Many postmenopausal women suffer from genitourinary syndrome of menopause (GSM) due to the lack of estrogen. This study aimed to evaluate the relationship between mode of delivery and GSM among postmenopausal women. METHODS: We performed a case-control study of women who had had either vaginal delivery or Cesarean section. Data were collected through a sociodemographic questionnaire and a check list for assessing signs and symptoms of GSM. Subjective symptoms of vaginal atrophy (dryness, dyspareunia, itching, burning and paleness), pH of the vagina and maturation index were assessed and recorded...
April 25, 2017: Climacteric: the Journal of the International Menopause Society
https://www.readbyqxmd.com/read/28419068/visual-improvements-in-vaginal-mucosa-correlate-with-symptoms-of-vva-data-from-a-double-blind-placebo-controlled-trial
#15
James A Simon, David F Archer, Risa Kagan, Brian Bernick, Shelli Graham, Ginger D Constantine, Sebastian Mirkin
OBJECTIVE: To evaluate the response of the vaginal mucosa with TX-004HR and its correlation with vulvar and vaginal atrophy (VVA) symptoms, and whether visual examination is a useful measure for assessing VVA. METHODS: REJOICE was a 12-week, phase 3, multicenter, randomized, double-blind, placebo-controlled study of a vaginal, muco-adhesive, 17β-estradiol softgel capsule (TX-004HR 4, 10, and 25 μg) in postmenopausal women with VVA and moderate-to-severe dyspareunia...
April 17, 2017: Menopause: the Journal of the North American Menopause Society
https://www.readbyqxmd.com/read/28398023/clinical-profile-of-women-with-vva-who-are-not-candidates-for-local-vaginal-oestrogen-therapy
#16
Rossella E Nappi, Filippo Murina, Giuseppina Perrone, Paola Villa, Nicoletta Biglia
Vulvar and vaginal atrophy (VVA) is a chronic medical condition in postmenopausal women, which is predominantly due to a permanent cessation of ovarian oestrogen production. Current available treatment options for VVA are over-the-counter (OTC) symptomatic relief products or local oestrogen therapy (LET) aiming to treat this underlying atrophic condition. Recent surveys indicated that these products decrease sexual spontaneity, are messy and indiscrete. Ospemifene is an oral daily drug, which has proven to treat vaginal dryness and dyspareunia effectively...
April 10, 2017: Minerva Ginecologica
https://www.readbyqxmd.com/read/28391746/management-of-vaginal-atrophy-a-real-mess-results-from-the-agata-study
#17
Federica Palma, Anjeza Xholli, Angelo Cagnacci
OBJECTIVES: To investigate the management of vaginal atrophy (VA) in a population-based study. STUDY DESIGN: A sub-study of a cross-sectional multicenter study on 913 postmenopausal women. MAIN OUTCOME MEASURES: Management of VA was investigated on the 274 women referring having received a previous diagnosis of VA. RESULTS: Women had received, no therapy (9.8%), systemic hormones (9.2%), intra-vaginal estrogens (44.5%) or local non-hormonal (36...
April 8, 2017: Gynecological Endocrinology
https://www.readbyqxmd.com/read/28381099/oxytocin-stimulates-cell-proliferation-in-vaginal-cell-line-vk2e6e7
#18
Theodora K Kallak, Kerstin Uvnäs-Moberg
Objective During and after menopause, the symptoms of vaginal atrophy cause great discomfort and necessitate effective treatment options. Currently, vaginally applied oxytocin is being investigated as a treatment for the symptoms of vaginal atrophy in postmenopausal women. To clarify the mechanisms behind oxytocins effects on vaginal atrophy, the present study investigated the effects of oxytocin on cell proliferation in the cells of the Vk2E6E7 line, a non-tumour vaginal cell line. The study also compared the effects of oxytocin with those of estradiol (E2)...
March 2017: Post Reproductive Health
https://www.readbyqxmd.com/read/28364869/a-vaginal-estradiol-softgel-capsule-tx-004hr-has-negligible-to-very-low-systemic-absorption-of-estradiol-efficacy-and-pharmacokinetic-data-review
#19
REVIEW
James A Simon, David F Archer, Ginger D Constantine, James H Pickar, Julia M Amadio, Brian Bernick, Shelli Graham, Sebastian Mirkin
This paper reviews the efficacy, safety, and systemic absorption of estradiol with TX-004HR, an investigational, low-dose 17β-estradiol vaginal softgel capsule, designed to treat vulvar and vaginal atrophy (VVA) in postmenopausal women, with an improved user experience. In phase 2 (NCT02449902) and phase 3 REJOICE (NCT02253173) studies, TX-004HR significantly improved the proportions of vaginal superficial and parabasal cells and vaginal pH, and in the phase 3 study decreased the severity of dyspareunia, vaginal dryness, and vulvar and/or vaginal itching or irritation...
May 2017: Maturitas
https://www.readbyqxmd.com/read/28355090/consistency-of-effect-with-a-low-dose-estradiol-vaginal-capsule-tx-004hr-evaluating-improvement-in-vaginal-physiology-and-moderate-to-severe-dyspareunia-in-subgroups-of-postmenopausal-women
#20
Ginger D Constantine, Celine Bouchard, James H Pickar, David F Archer, Shelli Graham, Brian Bernick, Sebastian Mirkin
BACKGROUND: The 12-week, randomized, double-blind, placebo-controlled, multicenter, phase 3 REJOICE trial demonstrated that TX-004HR, an investigational, applicator-free, low-dose vaginal softgel capsule containing solubilized 17β-estradiol, effectively and rapidly treats symptoms of vulvar and vaginal atrophy (VVA) with negligible to very low systemic absorption. The aim of this analysis was to assess whether the efficacy of TX-004HR varies with age, body mass index (BMI), uterine status, pregnancy status, and vaginal delivery...
June 2017: Journal of Women's Health
keyword
keyword
19676
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"